MétaCan
Menu
Back to cohort

Abstract B036: Non-steroidal anti-inflammatory drugs use and risk of colorectal cancer molecular subtypes: A systematic review and meta-analysis

2025· article· en· W4417201849 on OpenAlexaboutno aff
Mary Jose. Urruchúa-Rodríguez, Toktam Pour, Hermann Brenner, Michael Hoffmeister

Bibliographic record

VenueClinical Cancer Research · 2025
Typearticle
Languageen
FieldMedicine
TopicInflammatory mediators and NSAID effects
Canadian institutionsnot available
Fundersnot available
KeywordsColorectal cancerMicrosatellite instabilityCancerCpG siteMEDLINEMeta-analysisDrugRelative risk

Abstract

fetched live from OpenAlex

Abstract Background Current evidence suggests that the association between non-steroidal anti-inflammatory drug (NSAID) use and colorectal cancer (CRC) risk remains uncertain, and little is known about potential heterogeneity by molecular subtype. Clarifying these associations may provide insights into CRC carcinogenesis. The aim of this systematic review was to evaluate the association between NSAID use and CRC risk by four clinically relevant molecular subtypes. Methods PubMed, Web of Science and Embase were searched for studies assessing NSAID use in relation CRC risk by microsatellite instability (MSI), the CpG island methylator phenotype (CIMP), somatic mutations in the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene or the Kirsten rat sarcoma viral oncogene homolog gene (KRAS) status. Meta-analyses were performed to calculate summary relative risks (sRR). Results Nine studies met the inclusion criteria (n = 4,726 overall study population). NSAID use was associated with a stronger inverse association for BRAF-wildtype CRC (sRR = 0.73; 95% CI: 0.66–0.80) than for BRAF-mutated CRC (sRR = 0.85; 95% CI: 0.71–1.02), although the difference was not statistically significant (P heterogeneity = 0.11). Associations were in a similar direction for CIMP-high (sRR = 0.71; 95% CI: 0.61–0.83) and CIMP-low CRC (sRR = 0.73; 95% CI: 0.66–0.80), with no difference by CIMP status (P heterogeneity = 0.80). Similarly, risk reductions were observed for KRAS-mutated (sRR = 0.78; 95% CI: 0.69–0.88) and KRAS-wildtype (sRR = 0.76; 95% CI: 0.69–0.84), and for both MSI-high (sRR = 0.80; 95% CI: 0.67–0.96) and MSI-low/MSS CRC (sRR = 0.75; 95% CI: 0.69–0.82), with no evidence of heterogeneity by KRAS or MSI status (P heterogeneity = 0.76 and P heterogeneity = 0.51 respectively). Conclusion NSAID use was associated with lower risk of CRC across molecular subtypes, with suggestive differences by BRAF mutation status. These findings highlight the need for further studies to clarify potential subtype-specific associations and their implications for targeted chemoprevention strategies. Citation Format: Mary Jose. Urruchúa-Rodríguez, Toktam Pour, Hermann Brenner, Michael Hoffmeister. Non-steroidal anti-inflammatory drugs use and risk of colorectal cancer molecular subtypes: A systematic review and meta-analysis [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: The Rise in Early-Onset Cancers—Knowledge Gaps and Research Opportunities; 2025 Dec 10-13; Montreal, QC, Canada. Philadelphia (PA): AACR; Clin Cancer Res 2025;31(23_Suppl):Abstract nr B036.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.009
metaresearch head score (Gemma)0.023
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.016
Threshold uncertainty score0.045

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0090.023
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0160.033
Bibliometrics0.0070.009
Science and technology studies0.0010.001
Scholarly communication0.0030.002
Open science0.0020.001
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.089
GPT teacher head0.459
Teacher spread0.370 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueClinical Cancer ResearchSame topicInflammatory mediators and NSAID effectsFrench-language works237,207